Saturday, August 11, 2012

March 2012 Newsletter for Research Professionals


The Newsletter for Research Professionals     
March 2012

cancer research

Far Reaching Potential

There is a tremendous amount of research being conducted on all frontiers of oncology, ranging from cancer cell biology to chemotherapy treatment regimens and optimal palliative care and pain relief. This makes oncology a continuously changing field.  A Duke oncologist is warning that the emphasis on comparative effectiveness studies may present obstacles for the field of cancer research, Scientific American’s Observations blog reports.  At the recent American Association for Cancer Research confab, Duke’s Amy Abernethy outlined several obstacles, starting with the obvious notion that while oncology is increasingly moving towards personalized treatment, comparative effectiveness research is based on large populations. Therefore, patients whose tumors’ molecular abnormalities are not as common might fall through the research cracks.

There is also a dearth of evidence to actually direct physicians to the most “medically effective and cost-effective treatment for individual patients.” In addition, drugs being used off-label present their own dilemma. Observations notes, quoting Abernethy as saying between 50% and 70% of cancer drug prescriptions fall into that category. There is very little quality research focusing on those uses.
Suggestions for tackling the problem, in addition to randomized clinical trials: better data gathering from physicians and patients on the ground, and an “e-ecosystem” to encourage the electronic flow of information between all the parties involved in cancer research and treatment. Information in this article from The Wall Street Journal blog online.


Just as the largest library, badly arranged, is not so useful as a very moderate one that is well arranged, so the greatest amount of knowledge, if not elaborated by our own thoughts, is worth much less than a far smaller volume that has been abundantly and repeatedly thought over.



-Arthur Schopenhauer

Dedicated researchers seek better treatments and cures for diabetes, kidney disease, Alzheimer's and every form of cancer. But these scientists face an array of disincentives. We can do better.
Michael Milken

Need a Research Professional?

Clinical, legal, academic, marketing, quantitative, consulting, scientific, consumer! Every niche available to the research community is represented within our job search database. This is the most complimentary reflection we at ResearchNetwork have of our success in matching the right research candidates with the professional organizations that need them. Our service providers are the best in the industry. Our service buyers know this and that is why we are the most trusted employer/employee match-making service on the internet for research professionals.

We are proud to call some of the most dynamic companies in the world, with a focus on excellence in staff recruitment and management, our clients. If you are an employer interested in joining the ResearchNetwork network, we invite you to browse our site, become a member and join in our success.

To all of our members and guests, we welcome you and thank you for your ongoing interest. We hope you have enjoyed the information provided here. We would love to hear your thoughts on this and any other aspect of our site, please contact us anytime.

1 comment:

  1. Cancer is very hard disease and it directly affects your organs. I feel this disease and I know how tougher the things and how to control their mind at this stage but this dissertationcapital.com website is the best option for all. I love this information about this research and it is good for the people.

    ReplyDelete